Advisory Committee on Immunization Practices Meeting, 6006-6007 [2016-02080]

Agencies

• Centers for Disease Control and Prevention
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 81, Number 23 (Thursday, February 4, 2016)]
[Notices]
[Pages 6006-6007]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-02080]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Advisory Committee on Immunization Practices Meeting

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announce the following meeting of the aforementioned 
committee.

[[Page 6007]]


DATES: 8:00 a.m.-6:00 p.m., EST, February 24, 2016

ADDRESSES: CDC, Tom Harkin Global Communications Center, 1600 Clifton 
Road NE., Building 19, Kent ``Oz'' Nelson Auditorium, Atlanta, Georgia 
30329.
    Status: Open to the public, limited only by the space available. 
Time will be available for public comment. The public is welcome to 
submit written comments in advance of the meeting. Comments should be 
submitted in writing by email to the contact person listed below by 
February 15, 2016. All requests must contain the name, address, and 
organizational affiliation of the speaker, as well as the topic being 
addressed. Written comments should not exceed one single-spaced typed 
page in length and delivered in 3 minutes or less. Please note that the 
public comment period may end before the time indicated, following the 
last call for comments. Members of the public who wish to provide 
public comments should plan to attend the public comment session at the 
start time listed. Written comments received in advance of the meeting 
will be included in the official record of the meeting.
    The meeting will be webcast live via the World Wide Web; for 
instructions and more information on ACIP please visit the ACIP Web 
site: https://www.cdc.gov/vaccines/acip/.
    Purpose: The committee is charged with advising the Director, CDC, 
on the appropriate use of immunizing agents. In addition, under 42 
U.S.C. 1396s, the committee is mandated to establish and periodically 
review and, as appropriate, revise the list of vaccines for 
administration to vaccine-eligible children through the Vaccines for 
Children (VFC) program, along with schedules regarding the appropriate 
periodicity, dosage, and contraindications applicable to the vaccines. 
Further, under provisions of the Affordable Care Act, at section 2713 
of the Public Health Service Act, immunization recommendations of the 
ACIP that have been adopted by the Director of the Centers for Disease 
Control and Prevention and appear on the CDC immunization schedules 
must be covered by applicable health plans.
    Matters for Discussion: The agenda will include discussions on: 
Meningococcal vaccines; human papillomavirus vaccines; influenza; 
hexavalent vaccine (DTaP-IPV-Hib-HepB); cholera vaccine; Japanese 
encephalitis vaccine; and vaccine supply. A recommendation vote is 
scheduled for influenza. A Vaccines for Children (VFC) vote is 
scheduled for hexavalent vaccine (diphtheria and tetanus toxoids and 
acellular pertussis adsorbed (DTaP)--inactivated polio vaccine (IVP)--
Haemophilus influenzae type b (Hib)--hepatitis B (HepB).
    Agenda items are subject to change as priorities dictate.

FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, National Center for 
Immunization and Respiratory Diseases, CDC, 1600 Clifton Road NE., MS-
A27, Atlanta, Georgia 30329, telephone 404-639-8836; Email 
ACIP@CDC.GOV.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities for 
both the Centers for Disease Control and Prevention and the Agency for 
Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2016-02080 Filed 2-3-16; 8:45 am]
 BILLING CODE 4163-18-P